Suppr超能文献

不同包膜状态下巨大肝细胞癌经动脉化疗栓塞术与手术切除的对比:一项回顾性研究

Transarterial chemoembolization versus surgical resection for giant hepatocellular carcinoma under the different status of capsule: a retrospective study.

作者信息

Cai Xingchen, Wu Shengdong

机构信息

Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, China.

School of Medicine, Ningbo University, Ningbo, China.

出版信息

Transl Cancer Res. 2022 Dec;11(12):4359-4372. doi: 10.21037/tcr-22-2473.

Abstract

BACKGROUND

As an independent risk factor for the recurrence of hepatocellular carcinoma (HCC), the capsule has not been investigated in giant HCC (HCC ≥10 cm in diameter). In addition, whether the first line treatment for giant HCC should be surgery or transarterial chemoembolization (TACE) remains controversial. The aim of this study was to investigate the influence of tumor capsule on the prognosis of patients with giant HCC, and to compare the prognosis between surgical resection and TACE in giant HCC patients under different status of capsule to better inform surgeons.

METHODS

A retrospective review was conducted of all patients (n=83) who had been diagnosed with giant HCC and undergone surgical resection or TACE in the Affiliated Lihuili Hospital, Ningbo University, from January 2012 to December 2020. Among those who underwent surgical resection, overall survival (OS) and progression-free survival (PFS) were compared between patients with a complete capsule and with either an incomplete or no capsule. In patients with an incomplete/no capsule, survival outcomes were also compared between surgical resection and TACE. Prognostic factors for OS and PFS were analyzed in patients who underwent surgical resection.

RESULTS

In our study, 30 surgical patients had a complete capsule (Group 1), 33 surgical patients had an incomplete/no capsule (Group 2); 20 patients who had undergone TACE had an incomplete/no capsule (Group 3). The patient demographics were comparable, expect for liver segment invasion and tumor number, which suggested these 2 factors were related with capsule. Median OS was 39 months in Group 1, 27 months in Group 2, and 10 months in Group 3. Median PFS was 17 months in Group 1, 17 months in Group 2, and 7.5 in Group 3. There were significant statistical differences in OS and PFS between Group 1 and Group 2 (P=0.036; P=0.025). In patients who underwent surgical resection surgical time, liver segments invasion, and capsule were the independent risk factor for OS.

CONCLUSIONS

In giant HCC patients, complete tumor capsule could take a better long-term outcomes than incomplete or no tumor capsule. In addition, if possible, such patients should opt for surgical resection to obtain a better prognosis.

摘要

背景

作为肝细胞癌(HCC)复发的独立危险因素,肿瘤包膜在巨大HCC(直径≥10 cm的HCC)中尚未得到研究。此外,巨大HCC的一线治疗应选择手术还是经动脉化疗栓塞术(TACE)仍存在争议。本研究的目的是探讨肿瘤包膜对巨大HCC患者预后的影响,并比较在不同包膜状态下巨大HCC患者手术切除与TACE后的预后,以便为外科医生提供更充分的信息。

方法

对2012年1月至2020年12月期间在宁波大学附属李惠利医院被诊断为巨大HCC并接受手术切除或TACE的所有患者(n = 83)进行回顾性研究。在接受手术切除的患者中,比较有完整包膜的患者与包膜不完整或无包膜的患者的总生存期(OS)和无进展生存期(PFS)。在包膜不完整/无包膜的患者中,还比较手术切除与TACE后的生存结果。对接受手术切除的患者的OS和PFS的预后因素进行分析。

结果

在我们的研究中,30例手术患者有完整包膜(第1组),33例手术患者包膜不完整/无包膜(第2组);20例接受TACE的患者包膜不完整/无包膜(第3组)。除肝段侵犯和肿瘤数量外,患者的人口统计学特征具有可比性,这表明这两个因素与包膜有关。第1组的中位OS为39个月,第2组为27个月,第3组为10个月。第1组的中位PFS为17个月,第2组为17个月,第3组为7.5个月。第1组和第2组之间的OS和PFS存在显著统计学差异(P = 0.036;P = 0.025)。在接受手术切除的患者中,手术时间、肝段侵犯和包膜是OS的独立危险因素。

结论

在巨大HCC患者中,完整的肿瘤包膜比不完整或无肿瘤包膜的患者具有更好的长期预后。此外,此类患者应尽可能选择手术切除以获得更好的预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验